Varenicline: A Selective α4β2 Nicotinic Acetylcholine Receptor Partial Agonist Approved for Smoking Cessation
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Tobacco smoking remains a significant health problem in the United States. It has been associated with staggering morbidity and mortality, specifically due to malignancies and cardiovascular disease. Smoking cessation can be difficult and frequently requires pharmacologic interventions in addition to nonpharmacologic measures. Previously available agents are nicotine replacement products and bupropion, which increased quit rates by about 2-fold compared with placebo. Varenicline is the first drug in a new class known as the selective alpha4beta2 nicotinic receptor partial agonists. In several randomized, double-blind, 52-week clinical trials involving healthy chronic smokers, varenicline demonstrated superiority to placebo and bupropion in terms of efficacy measures. Additionally, it improved tobacco withdrawal symptoms and reinforcing effects of smoking in relapsed patients. Patients should start therapy in combination with tobacco cessation counseling 1 week before quit date and continue the regimen for 12 weeks. The dose of varenicline should be titrated to minimize nausea. The recommended dosage is 0.5 mg once daily (QD) on days 1-3; titrate to 0.5 mg twice daily (BID) on days 4-7; and 1 mg BID starting on day 8. An additional 12-week maintenance therapy may be considered for those who achieve abstinence. The most common side effects are nausea (30%), insomnia (18%), headache (15%), abnormal dreams (13%), constipation (8%), and abdominal pain (7%). Overall, varenicline is a breakthrough in the management of tobacco addiction and has demonstrated good efficacy in motivated quitters. It also provides an option for smokers who cannot tolerate other pharmacologic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
Shape of the relapse curve and long-term abstinence among untreated smokers
Hughes, J. R., Keely, J., & Naud, S. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00540.x · Cited by 1,414 · cited 1×
“Rates of success with self-quitting are low (3–5%) at 6–12 months after quitting.(3) Therefore, psychosocial support and pharmacologic aids are very important in helping a patient achieve abstinence from smoking.”
BackgroundGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 2×
“Varenicline 1 mg BID was further studied in a randomized, multicenter, double-blind, placebo- and bupropion-controlled phase 3 trial.(18) The study enrolled 1022 generally healthy chronic smokers who were between 18–75 years old.”
BackgroundCox, L. S., Tiffany, S. T., & Christen, A. G. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200020032051 · Cited by 1,188 · cited 1×
“Craving was assessed by item number 8, “the urge to smoke,” of the Minnesota Nicotine Withdrawal Scale (MNWS)(13) and the 10 items of the Brief Questionnaire of Smoking Urges (QSU-Brief).(14) Withdrawal was evaluated using the remaining 7 items of the MNWS.”
MethodVarenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930 · cited 1×
“It is a partial agonist highly selective for the 4 2 nicotinic acetylcholine receptors.(8) The 4 2 nicotinic receptors have been identified as a binding site for nicotine in the brain.”
BackgroundTonstad, S. (2006) · JAMA · doi:10.1001/jama.296.1.64 · Cited by 660
Nides, M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1561 · Cited by 390
Oncken, C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.15.1571 · Cited by 380
Foulds, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00955.x · Cited by 136 · cited 2×
“The moderate increase in dopamine levels is responsible for mimicking the effects of nicotine, thus reducing cravings.(9) The antagonist action blocks the reinforcing effect of nicotine, thus improving the likelihood of achieving abstinence from smoking without relapsing.”
Background
Cited by
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L. F., & Lancaster, T. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub4 · Cited by 46
Pace-Schott, E. F. (2011) · Principles and Practice of Sleep Medicine · doi:10.1016/b978-1-4160-6645-3.00048-7 · Cited by 19
Pace-Schott, E. F. (2008) · Serotonin and Sleep: Molecular, Functional and Clinical Aspects · doi:10.1007/978-3-7643-8561-3_12 · Cited by 8
Metadata
- Authors
- Lam, S., & Patel, P. N.
- Venue
- Cardiology in Review
- Published
- 2007-05
- Volume
- 15
- Issue
- 3
- Pages
- 154-161
- ISSN
- 1061-5377 (ISSN-L)
- OpenAlex
- W2023148023
- Cited by
- 41
- References
- 10
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline: A Selective α4β2 Nicotinic Acetylcholine Receptor Partial Agonist Approved for Smoking Cessation. https://app.cochat.ai/papers/10.1097/01.crd.0000260270.12829.45
- The paper
- Lam, S., & Patel, P. N. (2007). Varenicline: A Selective α4β2 Nicotinic Acetylcholine Receptor Partial Agonist Approved for Smoking Cessation. Cardiology in Review. https://doi.org/10.1097/01.crd.0000260270.12829.45
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.